cyrilzakka/clinical-trials huggingface dataset:
Implementation of an Epidemiological and Clinical Registry of Emergency Surgery Patients in a Costa Rican Hospital

A retrospective cross-sectional study was conducted in a quaternary level university hospital of the Costa Rican public health system. The study included all patients aged 12 years and older who required emergency surgery by the hospital's emergency surgery and trauma service, admitted through the hospital's emergency service.

This research consists in a retrospective cross-sectional study carried out in a quarterly level university hospital of care of the Costa Rican public health system (high complexity). The study included all patients aged 12 years or older who required emergency surgery for the hospital's emergency surgery and trauma service, admitted to this center between 2020 and 2022. Only those patients who required emergency surgery by another surgical specialty during this period were excluded from the register. A non-probabilistic convenience sampling was performed, based on the pre-established selection criteria and determined by the number of patients treated in the shock room of the hospital, that subsequently received general emergency or trauma surgery in the period under study. Sociodemographic variables, hemodynamic status, period of hospitalization, related to the procedure performed and the underlying comorbidities, as well as the clinical outcome, were included in the study database.

Eligibility Criteria:
Inclusion Criteria:

* The study included all patients aged 12 years and older who required emergency surgery by the hospital's emergency surgery and trauma service, admitted through the hospital's emergency service.

Exclusion Criteria:

* . Only those patients who required emergency surgery by another surgical specialty during this period were excluded from the register.
JAK-inhibition in Recurrent Classical Hodgkin Lymphoma

The Purpose of this trial is:

* to determine the overall response rate (ORR, complete response \[CR\] + partial response \[PR\]) in patients with relapsed or refractory HL
* to determine the safety profile of ruxolitinib in patients with relapsed or refractory HL


Eligibility Criteria:
Inclusion Criteria:

* relapsed or refractory HL
* ECOG \<= 2,
* no major organ dysfunction
* written informed consent

Exclusion Criteria:

* history of another primary malignancy ≤ 2 years
* female patients who are pregnant or breast feeding
* patients with a known history of HIV seropositivity
* chronic active hepatitis
Metabolic Control and Glycemic Variability in Type 1 Diabetes and Celiac Disease

This is an observational, retrospective study focused on differences of time-in-range and glycemic variability between a cohort of patients with both type 1 diabetes and celiac disease, and a cohort of patients with only type 1 diabetes.

The study design provides for 2 cohorts of pediatric and adolescent patients using the continuous glycemic monitoring sensor. Cohort A consists of patients with type 1 diabetes and celiace disease, while cohort B consists of patients with only type 1 diabetes.

The primary aim of the study is to assess whether cohort A patients can achieve the same metabolic control and glycemic variability goals (expressed as Time-In-Range and glycemic Variability Coefficient) as cohort B patients.

The secondary aims are: assessing differences in Time-In-Range and glycemic Variability Coefficient between cohort A patients treated with multidaily injections, and those treated with continuous subcutaneous insulin infusion; assessing differences on total daily insulinic intake between cohort A and cohort B.

Eligibility Criteria:
Inclusion Criteria:

* patients \< 18 years of age at enrollment;
* patients with type 1 diabetes onset since at least 1 year and celiac disease (COHORT A);
* patients only with type 1 diabetes onset since at least 1 year (COHORT B);
* using the continuous glycemic monitoring sensor;
* being on treatment with continuous subcutaneous insulin infusion or multidaily injections;
* obtaining informed consent from parents/legal guardian of pediatric patients.

Exclusion Criteria:

* patients with diabetes other than type1 diabetes;
* patients not using the glycemic monitoring sensor.
Dalpiciclib in HR+/HER2- ABC

To evaluate the efficacy and safety of dalpiciclib in patients with HR-positive/HER2-positive advanced breast cancer.


Eligibility Criteria:
Inclusion Criteria:

* Histologically confirmed advanced breast cancer
* Hormone receptor-positive and human epidermal growth factor receptor 2-negative
* ECOG 0-1

Exclusion Criteria:

* Pregnant or breastfeeding
* History of immunodeficiency
Occipital Nerve (C2) Stimulation in the Treatment of Fibromyalgia

The study is designed as a prospective, randomized, double-blind, single center study with a 6 month duration post permanent system implantation. Forty patients will be implanted.

During trial stimulation, patients will be randomized into one of two study arms for two weeks. Crossover will occur at the 2 week study visit to the opposite group. After completion of these two arms, every patient will subsequently complete participation in the third study arm.

After completion of the third arm, patients will be evaluated to determine if they are a positive responder responder. If so, the patient will have the option of obtaining the permanent implant.


Eligibility Criteria:
Inclusion Criteria:

1. Patients able to provide informed consent to participate in the study;
2. Patient has had chronic widespread pain for at least 3 months in all 4 body quadrants;
3. Patient has at least 11 out of 18 tender points based on the tender points examination;
4. Patient has attempted "best" medical therapy and has tried and failed at least three documented medically supervised treatments (including, but not limited to drugs, physical therapy, acupuncture, etc.);
5. Patient medication has remained stable for at least 4 weeks prior to baseline data collection;
6. Psychological screening has been completed and the patient has been cleared by a psychologist as a suitable study candidate;
7. Patient agrees not to add or increase medication throughout the randomization trial period of the study;
8. Patient is willing to cooperate with the study requirements including compliance with the treatment regimen and completion of all office visits.

Exclusion Criteria:

1. Patient has current evidence of any psychiatric disorder, as documented by the DSM-IV-TR criteria with psychotic characteristics, (e.g. bipolar disorder, major depressive disorder);
2. Patient has been diagnosed with any disease mimicking the symptoms of the Fibromyalgia Syndrome (e.g. Epstein Barr, autoimmune diseases, etc.) that is not currently being treated or has not been stable for at least 6 months;
3. Patient is currently in active menopause;
4. Patient has been diagnosed with sleep apnea and is not currently involved in a treatment regime;
5. Patient has a history of substance abuse or substance dependency in the past 6 months prior to baseline data collection;
6. Patient currently participating in another clinical study;
7. Patient with demand-type cardiac pacemakers, an infusion pump or any implantable neurostimulator device;
8. Patient is likely to require an MRI evaluation in the future;
9. Patient is not willing to maintain current medication regimen;
10. Female candidates of child bearing potential who are pregnant (confirmed by positive urine/blood pregnancy test), not using adequate contraception as determined by the investigator, or nursing (lactating) a child.
L-Arginine Treatment for Severe Vascular Fetal Intrauterine Growth Restriction: a Randomized Double Bind Controlled Trial (L Arginine in IUGR)

Although there is a strong rationale to supplement gravid patients suffering intrauterine growth restriction (IUGR) or preeclampsia with Arginine or other nitric oxide donors, evidence in the literature has been inconclusive. The current study was designed to determine whether oral treatment with L-Arginine, a nitric oxide (NO) donor, would enhance birth weight and/or decrease neonatal morbidity in pregnancies with severe vascular intrauterine growth restriction (IUGR).

Patients and Methods: 44 patients with a singleton pregnancy who had been referred for IUGR detected by ultrasonic examination were included. Vascular IUGR was defined by fetal abdominal circumference less than or equal to the third percentile, associated with abnormal uterine Doppler. After double blind randomization, patients received either 14 g/day of L-arginine (90 mL syrup, Veyron France Laboratories), or a placebo. Doppler ultrasound examination of the uterine, umbilical and cerebral circulation, and of ductus venosus was performed prior to inclusion, after 7 days of treatment, and the day before delivery. Ultrasound examination was performed upon randomization, and weekly until birth. Venous blood and urine samples were collected before initiation and after 7 days of treatment, and both maternal and umbilical venous samples were obtained at delivery for nitrate and nitrite (NO2-/ NO3-) determination.

Eligibility Criteria:
Inclusion Criteria:

* Multicenter randomized trial.
* Patients with a singleton pregnancy with IUGR defined by fetal abdominal circumference less than or equal to the third percentile for gestational age, and abnormal uterine Doppler. Uterine Doppler was considered pathologic if Pourcelot's resistance index (S-D/S) was equal to or higher than 0.7, and/or if an obvious notch was present. If the placenta was not median, the side of the pathologic Doppler had to be on the same side as the placenta

Exclusion Criteria:

* Acute fetal distress
* Non vascular and non severe IUGR (normal uterine doppler scans and/or abdominal circumference \> 3rd percentile)
* Maternal immune disorder
* IUGR from an infectious etiology
* IUGR associated with fetal malformation, multifetal pregnancy, and preeclampsia upon inclusion
A Study of TMC435 in Combination With Pegylated Interferon Alp\Fa-2a and Ribavirin in Patients Infected With Genotype 1 Hepatitis C Virus Who Never Received Treatment

The purpose of this study is to evaluate the efficacy of 4 different regimens of TMC435 in combination with peginterferon alfa-2a (PegIFNα-2a) and ribavirin (RBV), defined as the proportion of patients with sustained virologic response at Week 72 (patients with undetectable plasma HCV RNA \[less than 25 IU per mL undetectable\] at the end of treatment and at Week 72), compared to the control group receiving PegIFN and RBV in combination with TMC435-matched placebo.

This is a randomized (study medication assigned by chance), 5-arm, double-blind (neither investigator nor the participant knows the treatment that the participant receives), placebo-controlled (an inactive substance that is compared with the study medication to test whether the study medication has a real effect in clinical study) study to compare the efficacy, tolerability and safety of different TMC435 regimens combined with peginterferon alfa-2a (PegIFNα-2a) and ribavirin (RBV) versus PegIFNα-2a plus RBV alone in adult treatment-naive patients with chronic genotype 1 HCV infection. The study mainly consists of 3 phases: screening phase (approximately 6 weeks), treatment phase (up to 48 weeks), and follow up phase (up to 48 weeks). In the treatment phase, patients will be divided in to 5 different arms in a 1:1:1:1:1 randomized ratio. In treatment arms 1 and 2, patients will receive 12 weeks of therapy with TMC435 along with PegIFNα 2a and RBV followed by treatment with PegIFNα 2a, RBV, and TMC435-matched placebo. In treatment arms 3 and 4, patients will receive 24 weeks of therapy with TMC435, PegIFNα 2a, and RBV. In treatment arm 5 (control group), patients will receive PegIFNα 2a and RBV for 48 weeks and TMC435 matched placebo for the first 24 weeks. Collection of blood samples for efficacy evaluations will be done at scheduled visits throughout the study. Safety evaluations for adverse events, clinical laboratory tests, physical examination, vital signs and electrocardiogram will be monitored throughout the study. The total duration of the study will be up to approximately 72 weeks after initiation of treatment.

Eligibility Criteria:
Inclusion Criteria:

* Patients with documented chronic genotype-1 hepatitis C infection and with plasma HCV RNA of \> 100,000 IU/mL at screening
* Patients that have not been treated before for HCV
* Patients that are of childbearing potential or have a partner of childbearing potential should agree to use 2 effective methods of contraception

Exclusion Criteria:

* Patients with cirrhosis or evidence of hepatic decompensation
* Co-infection with the human immunodeficiency virus (HIV)
* Any contraindication to Pegasys or Copegus therapy
* History of, or any current medical condition which could impact the safety of the patient in the study
B-lines Score as Indicator for the Systemic Volumetric Load During TURP

Lung Ultrasonography score (LUS) using B-lines is a noninvasive, reliable and promising method for determining the extravascular lung water (EVLW). This was previously evaluated by trans-pulmonary thermodilution technique.

The transurethral resection of the prostate syndrome (TURP-S) is a potentially life-threatening complication of the TURP surgery and timely diagnosis of TURP-S is crucial for rapid detection and optimized treatment.

This observational study is designed to investigate the use of LUS using B-lines as a bed-side, simple, and non-invasive indicator for predication of the presence of systemic volume overload in patients undergoing endoscopic TURP.


Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 60 years.
* American Society of Anesthesiologists Classification (ASA ) I, II, and III.
* Full conscious patients.

Exclusion Criteria:

* Patient refusal.
* Who known allergic or hypersensitivity to any drug used in the study (local anesthesia).
* Coagulopathy (history of bleeding disorders), or patients on anticoagulant drugs, with (platelets \<50,000 International Normalised Ratio( INR)\>1.5).
* Patients have renal dysfunction patients with creatinine ≥ 2.
* Patients have uncontrolled cardiac diseases (IHD, (congestive heart failure (CHF), pulmonary hypertension and valvular diseases).
* Abdominal ascites.
* Patients with local infection at the site of local anesthetic injection.
* Failed spinal anesthesia.
* Timing not exceed 90 min.
* Any patient with lung ultrasound examination at T 0 ≥ 3 B-lines will be excluded from the study.
Disability, MRI Lesions and Thickness of Retinal Fibers: Evaluation 15 Years After a First Episode of Demyelination

Knowledge of the evolution of multiple sclerosis (MS) and its long-term prognostic factors is essential to guide the therapeutic management. However, it remains partial and concerns above all data collected during the first years of the disease. The evolution towards disability can only be assessed after a follow-up of more than 10 years and does not depend solely on the initial inflammatory activity of the disease. We propose to realize a standardized clinical assessment, an optical coherence tomography (OCT) and a cerebral MRI 15 years after the first clinical manifestation of the disease.

Clinical and paraclinical assessment will consist in the realization of additional MRI sequences in order to obtain more precise information on cerebral lesions (unconventional parameters). Optical coherence tomography (new generation device) will also be performed on both eyes to describe the thickness of the different layers of the retina. A clinical evaluation will be performed with the Expanded Disability Status Scale (EDSS).

This study aims:

1. to describe the current clinical situation of patients (e.g. percentage of patients with moderate or severe disability)
2. to explore the associations between MRI parameters, those measured with OCT and clinical characteristics (disability)
3. to explore clinical and paraclinical prognostic factors of pejorative evolution (disability, severe cerebral atrophy, etc.)


Eligibility Criteria:
Inclusion Criteria:

* First episode of demyelination occurred at least 10 years ago
* Hospitalized in the neurology department during this episode
* Insured with a social security scheme
* Having given his consent to participate in the study

Exclusion Criteria:

* Contraindications to 3 Tesla MRI and injection of contrast media
* Benefiting from a legal protection measure
* Pregnant or nursing mother
Genetic Investigation of Cancer Predisposition

Clinical information and samples (blood, saliva, and tumor) will be collected from patients with multiple cancers and/or a family history of cancer as well as from affected and unaffected relatives; samples will be systematically sequenced and evaluated for candidate driver mutations.

Genetic screening will be performed on DNA (and/or RNA) isolated from collected samples from affected individuals by whole exome sequencing or RNA sequencing using in-house pipeline to identify candidate sequence variants. These variants will be tested for segregation with the phenotype in other relatives (affected/unaffected). Candidate variants will be subjected to additional downstream analysis, to be guided by the actual type of gene/variant.

Eligibility Criteria:
Inclusion Criteria:

1. Any age
2. Meets at least ONE of the following:

   1. Personal history (with documented diagnosis) of cancer before the age of 50
   2. Personal history of more than one primary cancer
   3. Documented diagnosis of cancer AND family history of that same cancer type or multiple other cancers that do not fit classical criteria of hereditary cancer syndromes
   4. Documented diagnosis of a rare cancer AND family history of rare cancers that do not fit classical criteria of hereditary cancer syndromes
   5. There is the same type of cancer in several generations of a family
   6. Documented diagnosis of multicentric cancers (e.g bilateral cancers in paired organs, or multifocal cancers in single organs) that usually occur as single lesions when presented sporadically
   7. Early onset cancer (before the age of 50, or breast cancer before age 45) AND family history of early onset cancer Capable of providing access to detailed medical records and family history of cancer

Exclusion Criteria:

1. Established genetic diagnosis of a known hereditary cancer syndrome that is compatible with the clinical presentation
2. Incarcerated
Trilogy Stereotactic Body Radiotherapy for Pancreatic Cancer

This study will assess the efficacy of treating locally advanced pancreatic cancer using Stereotactic Body Radiotherapy (using Trilogy) and Gemcitabine

In this study, we propose to combine stereotactic body radiotherapy (SBRT) with standard gemcitabine chemotherapy. We hypothesize that earlier administration of systemic chemotherapy may prolong the interval to distant progression and improve overall survival in these patients. In this study, we will treat pancreatic cancer patients with locally advanced disease with 3 weeks of gemcitabine, followed by Trilogy(TM) SBRT and additional gemcitabine. 30 patients will be accrued to this study at Stanford University Medical Center, the only site participating in this research study. Treatment on this protocol requires placement of 3-5 gold (99.9% pure) fiducials for targeting purposes. Four to 7 days after placement of the fiducials, patients will then undergo a 4D pancreatic protocol CT scan through the upper abdomen. In addition, an FDG PET scan is required for treatment planning purposes. This imaging set will be processed for radiosurgery, using a modified linac based radiation treatment planning system (EclipseTM). An SBRT treatment plan will be developed based on tumor geometry and location. All patients will receive a single fraction of 25 Gy prescribed to the isodose line that completely surrounds the gross pancreatic tumor volume (GTV) as defined by the contrast CT. Following SBRT, patients will be monitored clinically and radiographically.

Eligibility Criteria:
Inclusion Criteria:- Pancreatic tumors not to exceed 10 cm in greatest axial dimension

* Histologically confirmed malignancies of the pancreas
* Unresectable by CT criteria or exploratory laparotomy or laparoscopy
* Patients with metastatic disease may be treated if they are symptomatic from the primary tumor
* Performance status of 0, 1, or 2
* No chemotherapy two weeks prior or two weeks following radiosurgery

Exclusion Criteria:

* patients who have had prior radiotherapy to upper abdomen
* patients receiving any prior pancreatic cancer therapy
* children, pregnant, and breastfeeding women, and lab personnel are excluded
* uncontrolled intercurrent illnesses
* any concurrent malignancy
Impact of Auriculotherapy on Postoperative Pain in Patients Undergoing Surgery for SCC

Auriculotherapy shows promising potential for pain management in patients with carpal tunnel syndrome (CTS). Studies have demonstrated encouraging results in pain reduction and improvement in quality of life. However, further research is required to strengthen these findings and fully integrate auriculotherapy into standard treatment protocols for CTS.

this prospective, double-blind comparative study aims to evaluate the effectiveness of auricular acupuncture in managing postoperative pain following outpatient carpal tunnel surgery


Eligibility Criteria:
Inclusion Criteria:

* Subjects aged over 20 years
* Patients with carpal tunnel syndrome scheduled for endoscopic surgery
* Patients who have never undergone auriculotherapy sessions before
* No participation in another clinical study

Exclusion Criteria:

* Patients under 20 years of age
* Unable to undergo medical follow-up for the study
* Legally protected adult subjects, under guardianship or curatorship
Training in Goal-directed Attention Regulation for Individuals With Brain Injury

Brain injuries affect the lives of numerous Veterans. This study examines how the brain is affected by injury and how rehabilitation training for attention dysfunction may change brain functioning.

Traumatic brain injuries (TBI) are a leading cause of long-term disability among combat Veterans. The most common and persistent sequelae after TBI are cognitive-behavioral deficits in 'executive control' and 'attention' functions. Such abnormalities may directly contribute to poor long-term outcomes as well as impede rehabilitation of dysfunction in other cognitive and motor domains. Effective treatments would potentially make a major impact in improving functional outcomes, but consistently effective treatments are not available. The overall goal of this research is to improve the investigators' understanding of plasticity in brain function after TBI and to develop improved cognitive neurorehabilitation treatments. The intervention involves individual and group-based training in cognitive skills.

Eligibility Criteria:
Inclusion Criteria:

* history of traumatic brain injury
* greater than 1 week from injury
* residual dysfunction related to attention and executive control

Exclusion Criteria:

* aphasia
* active illicit drug use
* severe depression
* contraindications to MRI scanning
Attention to Retinoblastoma Diagnosed in the Trauma Setting

To study the clinical characteristics and treatment outcomes of patients who experienced inadvertent trauma before diagnosis of retinoblastoma.

Retrospective study of the clinical characteristics and treatment outcomes of patients who experienced inadvertent trauma before diagnosis of retinoblastoma and to alert ophthalmologists to the possibility of RB in children presenting with or without trauma-related symptoms and signs.

Eligibility Criteria:
Inclusion Criteria:

* The consecutive patients with RB managed at the ocular oncology service of Zhongshan Ophthalmic Center, Sun Yat-sen University, between January 2013 and August 2018.

Exclusion Criteria:

* The patients who didn't have undergone trauma before diagnosis of RB.